Third-line chemotherapy for advanced non-small-cell lung cancer - Is there enough evidence to support its use?
Journal
Journal of the Chinese Medical Association
Journal Volume
68
Journal Issue
4
Pages
160-161
Date Issued
2005
Author(s)
Abstract
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. *Correspondence to: Dr. Chih-Hsin Yang, Department of Oncology, National Taiwan University Hospital, 7, Chung San South Road, Taipei 100, Taiwan, R.O.C. E-mail: [email protected] Received: October 6, 2004 • Accepted: December 9, 2004
SDGs
Other Subjects
antineoplastic agent; docetaxel; erlotinib; gefitinib; gemcitabine; ifosfamide; irinotecan; navelbine; paclitaxel; pemetrexed; platinum derivative; advanced cancer; blood toxicity; cancer combination chemotherapy; cancer survival; clinical trial; cross resistance; drug efficacy; drug indication; drug mechanism; drug targeting; drug use; editorial; evidence based medicine; human; lung non small cell cancer; meta analysis; patient selection; survival time
Publisher
Chinese Medical Association - Taipei
Type
editorial